Gilbert, AZ 的 非小細胞肺癌 臨床試驗
13 項針對 非小細胞肺癌 的研究正在 Gilbert(約 30 英里範圍內)及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本(英文)
正在為研究招募對象嗎?將此頁面置頂展示 — $99 / 30 天 →
Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
招募中1 期
- Banner MD Anderson Cancer Center, Gilbert
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
招募中3 期
- Banner MD Anderson Cancer Center ( Site 0181), Gilbert
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
招募中1 期
- Research Site, Gilbert
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
招募中觀察性研究
- Banner Health, Gilbert
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
招募中3 期
- Ironwood Cancer & Research Centers, Gilbert
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
招募中1/2 期
- Banner MD Anderson Cancer Center, Gilbert
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
招募中1/2 期
- Banner Health- MD Anderson Cancer Center, Gilbert
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- Banner MD Anderson Cancer Center, Gilbert
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
招募中3 期
- Research Site, Gilbert
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
招募中1/2 期
- Banner MD Anderson Cancer Center, Gilbert
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
招募中2 期
- Banner Health MD Anderson, Gilbert
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
招募中1/2 期
- Banner Health, Gilbert
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
招募中1/2 期
- Banner MD Anderson Cancer Center, Gilbert
其他城市的 非小細胞肺癌 試驗
- Houston, TX145 項研究
- New York City, NY121 項研究
- Arlington, VA104 項研究
- Nashville, TN97 項研究
- Boston, MA90 項研究
- Los Angeles, CA87 項研究
- St. Louis, MO73 項研究
- Chicago, IL61 項研究
- Baltimore, MD60 項研究
- San Antonio, TX59 項研究
- Columbus, OH57 項研究
- Washington, DC55 項研究
Gilbert 的其他研究
- 乳癌10 項研究
- 大腸直腸癌9 項研究
- 癌症(所有類型)8 項研究
- 肺癌8 項研究
- 膀胱癌6 項研究
- 心臟衰竭6 項研究
- 多發性骨髓瘤6 項研究
- 頭頸部鱗狀細胞癌6 項研究
- 心血管疾病6 項研究
- 轉移性癌症6 項研究
- 瀰漫性大B細胞淋巴瘤5 項研究
- 非霍奇金淋巴瘤5 項研究
資料來源:ClinicalTrials.gov,擷取日期 2026年10月6日。各研究自行設定資格標準;由研究團隊決定參與者資格。